<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01092949</url>
  </required_header>
  <id_info>
    <org_study_id>P 081111</org_study_id>
    <secondary_id>2009-A01024-63</secondary_id>
    <nct_id>NCT01092949</nct_id>
  </id_info>
  <brief_title>Reference Ranges for Placental Perfusion Using Magnetic Resonance Imaging (MRI)PLACENTIMAGE</brief_title>
  <official_title>Reference Ranges for Placental Perfusion Using Magnetic Resonance Imaging (MRI)PLACENTIMAGE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the feasibility of functional MRI method developed in an animal model and to&#xD;
      construct normal reference ranges for in vivo placental perfusion using functional MRI. This&#xD;
      will be based on imaging studies in patients undergoing termination of pregnancy (TOP) at 16&#xD;
      to 32 weeks' for fetal reason in a tertiary referral center.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective:&#xD;
&#xD;
      To evaluate the feasibility of functional MRI method developed in an animal model and to&#xD;
      construct normal reference ranges for in vivo placental perfusion using functional MRI. This&#xD;
      will be based on imaging studies in patients undergoing termination of pregnancy (TOP) at 16&#xD;
      to 32 weeks' for fetal reason in a tertiary referral center.&#xD;
&#xD;
      Method:&#xD;
&#xD;
      All patients undergoing TOP at 16 to 32 weeks will be offered to participate in this study.&#xD;
&#xD;
      120 patients will be included. 15 per group of weeks of gestation: 16+0-17+6 SA, 18+0-19+6&#xD;
      SA, 20+0-21+6 SA, 22+0-23+6 SA, 24+0-25+6 SA, 26+0-27+6 SA, 28+0-29+6 SA, 30+0-31+6 WG.&#xD;
&#xD;
      MRI will be performed in the same hospital, during hospital stay, within 45 minutes.&#xD;
&#xD;
      Two MRI sequences will be used to measure placental perfusion:&#xD;
&#xD;
        -  dynamic sequences using Gd contrast agent.&#xD;
&#xD;
        -  &quot; spin tagging &quot;, which do not need any contrast agent. Perfusion will be modelled using&#xD;
           compartmental analysis. Reference ranges will be build up by statistical modelling.&#xD;
           Gadolinium assays will be performed on amniotic fluid and placental tissue following&#xD;
           TOP.&#xD;
&#xD;
      Duration of inclusion: 24 months.&#xD;
&#xD;
      Duration of patient participation: 45 minutes.&#xD;
&#xD;
      Expected results:&#xD;
&#xD;
        -  Feasibility in routine practice.&#xD;
&#xD;
        -  Reference ranges for placental perfusion.&#xD;
&#xD;
        -  Comparison between the two measurements methods.&#xD;
&#xD;
      Adverse outcome measure:&#xD;
&#xD;
      Nausea, vomiting, lack of comfort and other adverse outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2010</start_date>
  <completion_date type="Actual">September 2018</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Establishment of physiological reference range of placental perfusion</measure>
    <time_frame>45 MIN</time_frame>
    <description>Establishment of physiological reference range of placental perfusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To quantify in vivo and by a not invasive way the microscopic physiological phenomena relative to the placental perfusion and in the local transcapillary exchanges of the placenta</measure>
    <time_frame>45 MIN</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between the two measurements methods.</measure>
    <time_frame>45 MIN</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">135</enrollment>
  <condition>Placental Insufficiency</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>MRI, 45 minutes</description>
    <other_name>MRI, 45 minutes</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients undergoing TOP at 16 to 32 weeks will be offered to participate in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women &gt; 18 years,&#xD;
&#xD;
          -  Undergoing TOP for fetal reason,&#xD;
&#xD;
          -  Informed signed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Placental adhesion anomaly,&#xD;
&#xD;
          -  Growth restriction,&#xD;
&#xD;
          -  Contrast agent allergy,&#xD;
&#xD;
          -  Absent consent,&#xD;
&#xD;
          -  Contraindication of MRI or Gadolinium,&#xD;
&#xD;
          -  Renal insufficiency,&#xD;
&#xD;
          -  Placental abnormality at pathological examination.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent Salomon, MCU PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Necker Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 26, 2010</study_first_submitted>
  <study_first_submitted_qc>March 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2010</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Placenta</keyword>
  <keyword>perfusion</keyword>
  <keyword>MRI</keyword>
  <keyword>spin tagging</keyword>
  <keyword>Gadolinium</keyword>
  <keyword>placental insufficiency</keyword>
  <keyword>urinary tract, sexual organs and pregnancy conditions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Placental Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

